Literature DB >> 17233533

Endocannabinoid mechanisms of pain modulation.

Andrea G Hohmann1, Richard L Suplita.   

Abstract

Cannabinoids are antinociceptive in animal models of acute, tissue injury-, and nerve injury-induced nociception. This review examines the biology of endogenous cannabinoids (endocannabinoids) and behavioral, neurophysiological, and neuroanatomical evidence supporting the notion that cannabinoids play a role in pain modulation. Behavioral pharmacological approaches, in conjunction with the identification and quantification of endocannabinoids through the use of liquid and gas chromatography mass spectrometry, have provided insight into the functional roles of endocannabinoids in pain modulation. Here we examine the distribution of cannabinoid receptors and endocannabinoid-hydrolyzing enzymes within pain modulatory circuits together with behavioral, neurochemical, and neurophysiological studies that suggest a role for endocannabinoid signaling in pain modulation. This review will provide a comprehensive evaluation of the roles of the endocannabinoids 2-arachidonoylglycerol and anandamide in stress-induced analgesia. These findings provide a functional framework with which to understand the roles of endocannabinoids in nociceptive processing at the supraspinal level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17233533      PMCID: PMC2751366          DOI: 10.1208/aapsj080479

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  154 in total

1.  Induction of c-fos-like protein in spinal cord neurons following sensory stimulation.

Authors:  S P Hunt; A Pini; G Evan
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

Review 2.  The many possible roles of opioids and related peptides in stress-induced analgesia.

Authors:  H Akil; E Young; J M Walker; S J Watson
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

3.  Antipyretic, analgesic and anti-inflammatory effects of delta 9-tetrahydrocannabinol in the rat.

Authors:  D S Kosersky; W L Dewey; L S Harris
Journal:  Eur J Pharmacol       Date:  1973-10       Impact factor: 4.432

4.  Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs.

Authors:  A C Howlett; J M Qualy; L L Khachatrian
Journal:  Mol Pharmacol       Date:  1986-03       Impact factor: 4.436

5.  Evidence for opioid and non-opioid forms of stimulation-produced analgesia in the rat.

Authors:  J T Cannon; G J Prieto; A Lee; J C Liebeskind
Journal:  Brain Res       Date:  1982-07-15       Impact factor: 3.252

6.  Opioid and nonopioid mechanisms of stress analgesia.

Authors:  J W Lewis; J T Cannon; J C Liebeskind
Journal:  Science       Date:  1980-05-09       Impact factor: 47.728

7.  9-nor-9beta-hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine.

Authors:  A S Bloom; W L Dewey; L S Harris; K K Brosius
Journal:  J Pharmacol Exp Ther       Date:  1977-02       Impact factor: 4.030

8.  Two opioid forms of stress analgesia: studies of tolerance and cross-tolerance.

Authors:  G W Terman; J W Lewis; J C Liebeskind
Journal:  Brain Res       Date:  1986-03-12       Impact factor: 3.252

9.  Chronic use of opioid analgesics in non-malignant pain: report of 38 cases.

Authors:  Russell K Portenoy; Kathleen M Foley
Journal:  Pain       Date:  1986-05       Impact factor: 6.961

10.  The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat.

Authors:  T L Yaksh
Journal:  J Clin Pharmacol       Date:  1981 Aug-Sep       Impact factor: 3.126

View more
  59 in total

Review 1.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

2.  Hemopressin is an inverse agonist of CB1 cannabinoid receptors.

Authors:  Andrea S Heimann; Ivone Gomes; Camila S Dale; Rosana L Pagano; Achla Gupta; Laura L de Souza; Augusto D Luchessi; Leandro M Castro; Renata Giorgi; Vanessa Rioli; Emer S Ferro; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

Review 3.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

4.  Mechanisms of exercise-induced hypoalgesia.

Authors:  Kelli F Koltyn; Angelique G Brellenthin; Dane B Cook; Nalini Sehgal; Cecilia Hillard
Journal:  J Pain       Date:  2014-12       Impact factor: 5.820

5.  The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.

Authors:  Mohammed A Issa; Sanjeet Narang; Robert N Jamison; Edward Michna; Robert R Edwards; David M Penetar; Ajay D Wasan
Journal:  Clin J Pain       Date:  2014-06       Impact factor: 3.442

Review 6.  Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.

Authors:  Armen N Akopian; Nikita B Ruparel; Nathaniel A Jeske; Amol Patwardhan; Kenneth M Hargreaves
Journal:  Trends Pharmacol Sci       Date:  2008-12-11       Impact factor: 14.819

Review 7.  The endocannabinoid system in obesity and type 2 diabetes.

Authors:  V Di Marzo
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

Review 8.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 9.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

10.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.